7-二乙氨基-3-(4-马来酸亚胺苯基-4-甲基香豆素 | 76877-33-3

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 中文名称: 7-二乙氨基-3-(4-马来酸亚胺苯基-4-甲基香豆素
• 中文别名: 2-氯-5-羟基甲基吡啶；1-(4-(7-(二乙氨基)-4-甲基-2-氧代-2H-苯并吡喃-3-基)苯基)-1H-吡咯-2,5-二酮；1-(4-(7-(二乙基氨基)-4-甲基-2-氧代-2H-色烯-3-基)苯基)-1H-吡咯-2,5-二酮
• 英文名称: 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin
• 英文别名: CPM；7-diethylamino-3-(4-maleimidophenyl)-4-methylcoumarin；N-(4'-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimide；1-[4-[7-(diethylamino)-4-methyl-2-oxochromen-3-yl]phenyl]pyrrole-2,5-dione
• CAS: 76877-33-3
• 化学式: C₂₄H₂₂N₂O₄
• mdl: MFCD00077334
• 分子量: 402.45
• InChiKey: YGIABALXNBVHBX-UHFFFAOYSA-N

物化性质

• 熔点：
  220-223°C
• 沸点：
  618.7±55.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.208
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• WGK Germany：
  3

制备方法与用途

用途：用作医药和农药中间体

反应信息

• 作为反应物：
  描述：

  N-(6-nitroveratryloxycarbonyl)-L-allo-thiothreonine 3'-pdCpA ester 、 7-二乙氨基-3-(4-马来酸亚胺苯基-4-甲基香豆素 以 水 、 乙腈 为溶剂， 反应 3.0h， 以64%的产率得到
  参考文献：
  名称：

  Synthesis of pdCpAs and transfer RNAs activated with thiothreonine and derivatives

  摘要：

  N,S-diprotected L-thiothreonine and L-allo-thiothreonine derivatives were synthesized using a novel chemical strategy, and used for esterification of the dinucleotide pdCpA. The aminoacylated dinucleotides were then employed for the preparation of activated suppressor tRNA(CUA) transcripts. Thiothreonine and allo-thiothreonine were incorporated into a predetermined position of a catalytically competent dihydrofolate reductase (DHFR) analogue lacking cysteine, and the elaborated proteins were derivatized site-specifically at the thiothreonine residue with a fluorophore. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.02.024

文献信息

• [EN] NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS<br/>[FR] NOUVEAUX INHIBITEURS À PETITES MOLÉCULES DE FACTEURS DE TRANSCRIPTION TEAD
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2020190774A1

  公开（公告）日：2020-09-24

  The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

  本公开涉及化合物及其组合物和使用方法。这些化合物抑制TEAD转录因子的活性，并可用于治疗与TEAD转录因子活性相关的疾病，例如癌症和其他疾病。
• [EN] HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE LA SYNTHÈSE DES LIPIDES ET COMBINAISONS EN CONTENANT
  申请人：3 V BIOSCIENCES INC

  公开号：WO2015095767A1

  公开（公告）日：2015-06-25

  Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

  提供了杂环调节剂脂质合成以及其药用盐；包括这些化合物的药物组合物；以及通过给予这些化合物和其他治疗剂的组合来治疗脂肪酸合酶途径失调症状的方法。
• [EN] ARGINASE INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'ARGINASE ET PROCÉDÉS D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2019177873A1

  公开（公告）日：2019-09-19

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.

  本文描述了化合物I的结构或其药用盐。化合物I作为精氨酸酶抑制剂，可用于预防、治疗或作为精氨酸酶相关疾病的治疗剂。
• [EN] AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS<br/>[FR] AZABENZAMIDAZOLES COMME INHIBITEURS D'ACIDE GRAS SYNTHASE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011066211A1

  公开（公告）日：2011-06-03

  This invention relates to the use of azabenzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of azabenzimidazoles in the treatment of cancer.

  这项发明涉及使用吡唑苯并咪唑衍生物来调节，特别是抑制脂肪酸合成酶（FAS）的活性或功能。适当地，本发明涉及在癌症治疗中使用吡唑苯并咪唑。
• AMPHIPATHIC COMPOUND HAVING NOVEL PENTA-SACCHARIDE HYDROPHILIC GROUP AND USE THEREOF
  申请人：Industry-University Cooperation Foundation Hanyang University Erica Campus

  公开号：US20190169218A1

  公开（公告）日：2019-06-06

  Disclosed are an amphipathic compound having a penta-saccharide hydrophilic group, a method of preparing the same, and a method of extracting, solubilizing, stabilizing, crystallizing or analyzing membrane proteins and membrane protein complexes using the same. In particular, since the compound has a high-density penta-saccharide hydrophilic group composed of five glucose units, the compound may have an excellent effect on crystallization of membrane proteins. In addition, since the hydrophilic group used in the amphipathic compound has a novel structure, the hydrophilic group may be applied to the development of various amphipathic molecules.

  披露了一种具有戊糖水基团的亲水性化合物，其制备方法以及使用该化合物提取、溶解、稳定、结晶或分析膜蛋白和膜蛋白复合物的方法。特别是，由于该化合物具有由五个葡萄糖单位组成的高密度戊糖水基团，该化合物可能对膜蛋白结晶具有显著效果。另外，由于在两亲性化合物中使用的亲水基团具有新颖的结构，该亲水基团可应用于各种两亲性分子的开发。